Inaction over the next few months could cost tens of thousands of lives. Here are things you should do now to stay safe and to stop the spread of the coronavirus.
Academic rigor, journalistic flair
Articles on COVID-19 vaccines
Displaying 521 - 540 of 576 articles
Early data shows that vaccines work for older people who are more at risk of severe COVID-19.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
Asking these four questions can help us identify good news when we see it, be more critical of news reports, or delay our judgement until we have more information.
There are two new COVID-19 vaccines that appear to be more than 90% effective. But what are these vaccines, and how are they different from those used previously?
A private market should have no place in the rollout of a COVID vaccine.
We will struggle to find a vaccine that works perfectly for people who need it most, despite what the headlines say is coming in 2021.
Moderna’s shot is far easier to store and distribute than Pfizer’s. But there are concerns neither vaccine performs particularly well for older people.
Whatever approach is taken, the vaccine roll-out has to be fair and efficient.
There’s no guarantee future COVID-19 vaccines will work in the elderly. So we can consider vaccinating the young first to protect them. Here’s what we need to work out first.
Personal stories work better than statistics when it comes to converting sceptics.
Promising vaccines such as Pfizer’s will play a role in ending the pandemic – but widespread immunity isn’t yet on the horizon.
Watch two of Australia and New Zealand’s top vaccine and virus experts answering questions about COVID-19. This was filmed at a Conversation reader event with Avid Reader bookshop.
The Pfizer/BioNTech vaccine may be rolled out in mere weeks.
Side agreements signed by some wealthy nations threaten to undercut global efforts to ensure a fairly equitable worldwide vaccination effort.
The TRIPS waiver makes COVID-19 treatments more accessible globally by enabling manufacture and distribution of COVID-19 drugs and medical supplies that would normally be protected by patents.
Two more COVID-19 vaccines may now be on the cards for Australia, should they pass clinical trials. But, as with earlier vaccine deals, there are no guarantees.
So-called mRNA vaccines are among the frontrunners in the global race to design a COVID vaccine. But as a new technology, most nations, including Australia, lack the capacity to produce them at scale.
People who oppose vaccines often are dismissed as ignorant or naive. Failing to hear their concerns and address them may only be fueling vaccine resistance, however.
If Indonesia can maximise its role as the hub for the production and distribution of Chinese COVID-19 vaccines for Southeast Asia region, the country may gain profits.
Top contributors
-
Associate professor, UNSW Sydney
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute
-
Associate Professor, School of Social Sciences, The University of Western Australia
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor, Epidemiology, Deakin University
-
Associate Professor, School of Biomedical Sciences and Pharmacy, University of Newcastle
-
Assistant Professor of Political Science, Oklahoma State University
-
Instructor of Human Immunology, Emory University
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Immunology, Vice-Chancellors Distinguished Professorial Fellow, Head of Immunology and Translational Research, Victoria University
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
-
Chair in Epidemiology, Deakin University
